Phage display (PD) is a technology based on the presentation of functional exogenous peptides on the capsid surface of bacteriophages. PD is performed by introducing a DNA sequence of interest at a specific position within a functional viral gene. In addition, peptide phage libraries are powerful tools for expressing a wide range of random peptides and for specific peptide screening. Specifically, PD applications include the analysis of binding and interactions between proteins, the identification of bioactive peptides that bind to receptors, the identification of disease-associated antigens, and the identification of cell-specific peptides. Since its emergence, PD technology has revolutionized several fields in the biological sciences, such as oncology, cell biology, and pharmacology, the innumerable applications for which will be described throughout this review.
Hamzeh-MivehroudMAlizadehAAMorrisMB. Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov. Today2013;18:1144–1157.
WuC-HLiuI-JLuR-M. Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci. 2016;23:8.
10.
WHO | World Health Organization. http://www.who.int. Accessed May 3, 2018.
11.
CraigRLiS. Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs. Mini Rev Med Chem. 2006;6:757–764.
12.
BrayFFerlayJSoerjomataramI. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
13.
DaiXCaiCXiaoF. Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library. Biochem Biophys Res Commun. 2014;445:795–801.
14.
ParkH-YLeeK-JLeeS-J. Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol Biotechnol. 2012;51(3):212–220.
15.
SunJZhangCLiuG. A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin Exp Metastasis. 2012;29(3):185–196.
16.
FagbohunOABediDJayannaPK. Landscape phage probes for breast cancer cells. In: Technical Proceedings of the 2008 Nanotechnology Conference and Trade Show, NSTI Nanotech. 2008:1–5.
17.
LiuFQiC-LKongM. Screening specific polypeptides of breast cancer stem cells from a phage display random peptide library. Oncol Lett. 2016;12:4727–4731.
YehC-YHsiaoJ-KWangY-P. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Biomaterials. 2016;99:1–15.
21.
JayannaPKBediDDeinnocentesP. Landscape phage ligands for PC3 prostate carcinoma cells. Protein Eng Des Sel. 2010;23(6):423–430.
22.
PengYZhangXPraterA. Targeting aggressive prostate cancer cell-associated CD44v6 using phage display selected peptides. J Nucl Med. 2017;58:624.
23.
WangWChenXLiT. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Exp Cell Res. 2013;319(8):1156–1164.
24.
SoendergaardMNewton-NorthupJRDeutscherSL. Original article in vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging. Am J Nucl Med Mol Imaging. 2014;4:561–570.
25.
MaCYinGYanD. A novel peptide specifically targeting ovarian cancer identified by in vivo phage display. J Pept Sci.2013;19(12):730–736.
26.
WangLWangLHuY. Identification of a peptide specifically targeting ovarian cancer by the screening of a phage display peptide library. Oncol Lett. 2016;11:4022–4026.
27.
ZhouCKangJWangX. Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models. BMC Cancer. 2015;15:889.
28.
WangC-HWengC-HCheY-J. Cancer cell-specific oligopeptides selected by an integrated microfluidic system from a phage display library for ovarian cancer diagnosis. Theranostics. 2015;5:431–442.
29.
LiHMGuoKYuZ. Diagnostic value of protein chips constructed by lung-cancer-associated markers selected by the T7 phage display library. Thorac Cancer. 2015;6(4):469–474.
30.
LeeKJLeeJHChungHK. Novel peptides functionally targeting in vivo human lung cancer discovered by in vivo peptide displayed phage screening. Amino Acids. 2015;47(2):281–289.
31.
LeeKJLeeJHChungHK. Application of peptide displaying phage as a novel diagnostic probe for human lung adenocarcinoma. Amino Acids. 2016;48(4):1079–1086.
32.
LeeS-MLeeE-JHongH-Y. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res2007;5:11–19.
33.
SunXNiuGYanY. Phage display derived peptides for osteosarcoma imaging. Clin Cancer Res. 2010;16(6):4268–4277.
34.
SamoylovaTIPetrenkoVAMorrisonNE. Phage probes for malignant glial cells. Mol Cancer Ther. 2003;2(11):1129–1137.
35.
ZhangZXuLWangZ. Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. J Clin Lab Anal. 2011;25(6):402–408.
36.
ZhangW-JSuiY-XBudhaA. Affinity peptide developed by phage display selection for targeting gastric cancer. World J Gastroenterol. 2012;18:2053–2060.
37.
BediDGillespieJWPetrenkoVA. Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. Protein Eng Des Sel. 2014;27:235–243.
38.
DyeC. After 2015: infectious diseases in a new era of health and development. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130426.
39.
Portes L daSKioshimaESde CamargoZP. Subtractive phage display selection for screening and identification of peptide sequences with potential use in serodiagnosis of paracoccidioidomycosis caused by Paracoccidioides brasiliensis. Lett Appl Microbiol. 2017;65(5):346–353.
40.
AlbanSMDe MouraJFThomaz-SoccolV. Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy. PLoS One. 2014;9: e106222.
41.
LinkJSAlbanSMSoccolCR. Synthetic peptides as potential antigens for cutaneous leishmaniosis diagnosis. J Immunol Res. 2017;2017:5871043.
42.
Toledo-MachadoCMBuenoLLMenezes-SouzaD. Use of phage display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes. Parasit Vectors. 2015;8:133.
EdaKEdaSShermanIW. Identification of peptides targeting the surface of Plasmodium falciparum-infected erythrocytes using a phage display peptide library. Am J Trop Med Hyg. 2004;71(2):190–195.
45.
CheongFWFongMYLauYL. Identification and characterization of epitopes on Plasmodium knowlesi merozoite surface protein-142 (MSP-142) using synthetic peptide library and phage display library. Acta Trop. 2016;154:89–94.
46.
BaldwinMRLiXHanadaT. Merozoite surface protein 1 recognition of host glycophorin A mediates malaria parasite invasion of red blood cells. Blood. 2015;125:2704–2711.
47.
Vega-RodriguezJPerez-BarretoDRuiz-ReyesA. Targeting molecular interactions essential for Plasmodium sexual reproduction. Cell Microbiol. 2015;17(11):1594–1604.
48.
Ghosh aKRibollaPEJacobs-LorenaM. Targeting Plasmodium ligands on mosquito salivary glands and midgut with a phage display peptide library. Proc Natl Acad Sci U S A. 2001;98(23):13278–13281.
49.
MukherjeeDMishraPJoshiM. EWGWS insert in Plasmodium falciparum ookinete surface enolase is involved in binding of PWWP containing peptides: Implications to mosquito midgut invasion by the parasite. Insect Biochem Mol Biol. 2016;68:13–22.
50.
RuizAPérezDMuñozMC. Targeting essential Eimeria ninakohlyakimovae sporozoite ligands for caprine host endothelial cell invasion with a phage display peptide library. Parasitol Res. 2015;114(11):4327–4331.
51.
YangLCenJXueQ. Identification of rabies virus mimotopes screened from a phage display peptide library with purified dog anti-rabies virus serum IgG. Virus Res. 2013;174(1-2):47–51.
52.
LarraldeOGMartinezRCamachoF. Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J Virol Methods. 2007;140(1-2):49–58.
53.
LamC-WAbuBakarSChangL-Y. Identification of the cell binding domain in Nipah virus G glycoprotein using a phage display system. J Virol Methods. 2017;243:1–9.
54.
LiuKHuanBShaoD. Peptide P3 selected from phage display screen shows antiviral activity against porcine reproductive and respiratory syndrome virus [published online ahead of print February 24, 2016]. J Biomed Sci. doi:10.4172/2254-609X.100024.
55.
YinLLuoYLiangB. Specific ligands for classical swine fever virus screened from landscape phage display library. Antiviral Res. 2014;109:68–71.
56.
WangMLiXChenJ. Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique. Rheumatol Int. 2011;31(8):1009–1016.
57.
WengXLiaoQLiK. Screening serum biomarker of knee osteoarthritis using a phage display technique. Clin Biochem. 2012;45(4-5):303–308.
58.
AraujoGRVazERFujimuraPT. Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. Arthritis Res Ther. 2015;17:168.
59.
SunYTanJYinX. Regulation of osteoblast differentiation by affinity peptides of TGF-β1 identified via phage display technology. ACS Biomater Sci Eng. 2018;4(7):2552–2562.
60.
ParkJPCropekDMBantaS. High affinity peptides for the recognition of the heart disease biomarker troponin I identified using phage display. Biotechnol Bioeng. 2010;105(4):678–686.
61.
YangJFullerPJMorganJ. Use of phage display to identify novel mineralocorticoid receptor-interacting proteins. Mol Endocrinol. 2014;28(9):1571–1584.
62.
PadmanabanGParkHChoiJS. Identification of peptides that selectively bind to myoglobin by biopanning of phage displayed-peptide library. J Biotechnol. 2014;187:43–50.
63.
GhoshalSBondadaVSaatmanKE. Phage display for identification of serum biomarkers of traumatic brain injury. J Neurosci Methods. 2016;272:33–37.
64.
LiJZhangQPangZ. Identification of peptide sequences that target to the brain using in vivo phage display. Amino Acids. 2012;42:2373–2381.
65.
LinzhiYDanCArhinSK. Screening for novel peptides specifically binding to the surface of ectopic endometrium cells by phage display. Cell Mol Biol (Noisy-le-grand). 2018;64:36–40.
66.
ZhaoYWangQJinY. Discovery and characterization of a high-affinity small peptide ligand, H1, targeting FGFR2IIIc for skin wound healing. Cell Physiol Biochem. 2018;49(3):1033–1048.
67.
SuireCNNainarSFazioM. Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display. PLoS One. 2018;13:e0193101.
68.
SakamotoKKanematsu-YamakiYKamadaY. Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology. Biochem Biophys Rep. 2017;11:33–39.
69.
WestwaterCKasmanLMSchofieldDA. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003;47:1301–1307.
70.
VaksLBenharI. In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines. J Nanobiotechnol. 2011;9:58.
HarhalaMBarylskiJHumińska-LisowskaK. Two novel temperate bacteriophages infecting Streptococcus pyogenes: their genomes, morphology and stability. PLoS One. 2018;13:e0205995.
73.
JayannaPKTorchilinVPPetrenkoVA. Liposomes targeted by fusion phage proteins. Nanomedicine. 2009;5(1):83–89.
74.
LoiMDi PaoloDSosterM. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. J Control Release. 2013;170(2):233–241.
75.
ChenYShenYGuoX. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol. 2006;24:455–460.
76.
BrunoBJMillerGDLimCS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4:1443–1467.
77.
OmidfarKDaneshpourM. Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015;10(6):651–669.
